BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 12924019)

  • 21. Kinetics of the reactions between streptokinase, plasmin and alpha 2-antiplasmin.
    Cederholm-Williams SA; De Cock F; Lijnen HR; Collen D
    Eur J Biochem; 1979 Oct; 100(1):125-32. PubMed ID: 158524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin.
    Rijken DC; Groeneveld E; Kluft C; Nieuwenhuis HK
    Biochem J; 1988 Oct; 255(2):609-15. PubMed ID: 2974279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circular dichroism studies on alpha 2-antiplasmin and its interactions with plasmin and plasminogen.
    Nilsson T; Sjöholm I; Wiman B
    Biochim Biophys Acta; 1982 Jul; 705(2):264-70. PubMed ID: 6214280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of the kringle domain in plasminogen activation with staphylokinase.
    Arai K; Madoiwa S; Mimuro J; Asakura S; Matsuda M; Sako T; Sakata Y
    J Biochem; 1998 Jan; 123(1):71-7. PubMed ID: 9504411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of alpha 2-plasmin inhibitor on plasminogen activation by staphylokinase/plasminogen complex.
    Okada K; Nonaka T; Matsumoto H; Fukao H; Ueshima S; Matsuo O
    Thromb Res; 1994 Oct; 76(2):211-20. PubMed ID: 7863470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.
    Kluft C; Nieuwenhuis HK; Rijken DC; Groeneveld E; Wijngaards G; van Berkel W; Dooijewaard G; Sixma JJ
    J Clin Invest; 1987 Nov; 80(5):1391-400. PubMed ID: 2445779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On the molecular interactions between plasminogen-staphylokinase, alpha 2-antiplasmin and fibrin.
    Lijnen HR; Van Hoef B; Matsuo O; Collen D
    Biochim Biophys Acta; 1992 Jan; 1118(2):144-8. PubMed ID: 1730031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasminogen binding sites in normal human skin.
    Burge SM; Marshall JM; Cederholm-Williams SA
    Br J Dermatol; 1992 Jan; 126(1):35-41. PubMed ID: 1311189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contribution of conserved lysine residues in the alpha2-antiplasmin C terminus to plasmin binding and inhibition.
    Lu BG; Sofian T; Law RH; Coughlin PB; Horvath AJ
    J Biol Chem; 2011 Jul; 286(28):24544-52. PubMed ID: 21543325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences between neonates and adults in carbohydrate sequences and reaction kinetics of plasmin and alpha(2)-antiplasmin.
    Ries M; Easton RL; Longstaff C; Zenker M; Morris HR; Dell A; Gaffney PJ
    Thromb Res; 2002 Feb; 105(3):247-56. PubMed ID: 11927131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-molecular-mass and low-molecular-mass kininogens block plasmin-induced platelet aggregation by forming a complex with kringle 5 of plasminogen/plasmin.
    Selim TE; Ghoneim HR; Uknis AB; Colman RW; DeLa Cadena RA
    Eur J Biochem; 1997 Dec; 250(2):532-8. PubMed ID: 9428707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of plasminogen activation by the plasmin-staphylokinase complex in plasma of alpha2-antiplasmin-deficient mice.
    Okada K; Ueshima S; Tanaka M; Fukao H; Matsuo O
    Blood Coagul Fibrinolysis; 2000 Oct; 11(7):645-55. PubMed ID: 11085285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of staphylokinase with different molecular forms of plasminogen.
    Lijnen HR; Van Hoef B; Collen D
    Eur J Biochem; 1993 Jan; 211(1-2):91-7. PubMed ID: 8425556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesis.
    Wang H; Doll JA; Jiang K; Cundiff DL; Czarnecki JS; Wilson M; Ridge KM; Soff GA
    Cancer Res; 2006 Jul; 66(14):7211-5. PubMed ID: 16849568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Production of the modified form of human plasminogen by alpha 2-macroglobulin-plasmin complexes.
    Yamamoto J; Okamoto U; Morita S; Asada N; Yamaoka M
    Jpn J Physiol; 1985; 35(6):1013-21. PubMed ID: 2422420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Inhibition of the process of Glu-plasminogen activation by tissue activator with fibrin, DDE-complex, and D-dimer using alpha-2-antiplasmin].
    Hrynenko TV; Zadorozhna MB; Platonova TM; Volkov HL
    Ukr Biokhim Zh (1999); 2005; 77(5):45-51. PubMed ID: 16846069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Regulation with alpha-2-antiplasmin of Glu-plasminogen activation by tissue activator on fibrin].
    Hrynenko TV; Zadorozhna MB; Iusova OI
    Ukr Biokhim Zh (1999); 2006; 78(3):106-12. PubMed ID: 17100317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of the plasminogen-binding site of human alpha 2-plasmin inhibitor.
    Sasaki T; Morita T; Iwanaga S
    J Biochem; 1986 Jun; 99(6):1699-705. PubMed ID: 3745142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The human alpha(2)-plasmin inhibitor: functional characterization of the unique plasmin(ogen)-binding region.
    Gerber SS; Lejon S; Locher M; Schaller J
    Cell Mol Life Sci; 2010 May; 67(9):1505-18. PubMed ID: 20112045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction of SK-human plasmin, SK-dog plasmin complexes with alpha 2-antiplasmin and alpha 2-macroglobulin.
    Reddy KN; Cercek B; Lew AS; Ganz W
    Thromb Res; 1986 Mar; 41(5):671-80. PubMed ID: 2421434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.